Alongside FY2019 results, Advanced Oncotherapy ("AVO") announced two new debt facilities which provide access to an additional c.£42m in strategic financing. The financing provides greater financial stability and flexibility for AVO moving forward, allowing the company to progress the development of the LIGHT system towards regulatory approval. LIGHT is now largely de-risked from a technology perspective, in our opinion, with development activities focused on the verification and valida
03 Jul 2020
Financing facilities totalling £42m announced alongside FY2019 results
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Financing facilities totalling £42m announced alongside FY2019 results
Advanced Oncotherapy Plc (AVO:LON) | 1.9 0 0.0% | Mkt Cap: 10.4m
- Published:
03 Jul 2020 -
Author:
KIERON BANERJEE -
Pages:
14
Alongside FY2019 results, Advanced Oncotherapy ("AVO") announced two new debt facilities which provide access to an additional c.£42m in strategic financing. The financing provides greater financial stability and flexibility for AVO moving forward, allowing the company to progress the development of the LIGHT system towards regulatory approval. LIGHT is now largely de-risked from a technology perspective, in our opinion, with development activities focused on the verification and valida